Trials / Completed
CompletedNCT02218190
Alvimopan and Ileus in PSF
A Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine with Alvimopan reduces the incidence of post operative ileus in patients who undergo posterior spinal fusion.
Detailed description
Posterior spinal fusion (PSF) is a common orthopaedic procedure associated with a high incidence of post-operative ileus (POI) and concomitant increased length of hospital stay (LOHS). POI is exacerbated by high dose opiate consumption often required by these patients post-operatively. We propose a randomized, double-blinded, placebo-controlled pilot trial studying the use of alvimopan, a peripherally-acting mu-opioid receptor antagonist known to reduce POI in bowel resection. We hypothesize that alvimopan will shorten POI in spine fusion patients without negatively affecting post-operative pain control. Treatment efficacy will be assessed by recording time to first bowel movement, time to hospital discharge, and post-operative pain control. We hypothesize that acute administration of alvimopan, a peripherally-acting mu-opioid antagonist, shortens the duration of post-operative ileus (POI) in patients undergoing long-segment (5 or greater thoracolumbar levels) posterior spinal fusion (PSF). The study will be a randomized, double-blinded, placebo-controlled pilot trial. Reducing the morbidity of POI in patients undergoing PSF will decrease hospital stay and costs, and also improve patient satisfaction and post-operative care after major orthopaedic surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alvimopan | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-01-01
- Completion
- 2019-01-01
- First posted
- 2014-08-18
- Last updated
- 2019-05-17
- Results posted
- 2019-05-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02218190. Inclusion in this directory is not an endorsement.